⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521276 | 0.78 | POLB (0.48) | — | |
| SCHEMBL27552583 | 0.74 | — | — | |
| Ampyzine SCHEMBL160265 | 0.74 | — | — | |
| Ampyzine SCHEMBL30627403 | 0.74 | — | — | |
| SCHEMBL13367380 | 0.74 | POLB (0.55) | — | |
| Ampyzine SCHEMBL160879 | 0.72 | POLB (0.53) | — | |
| SCHEMBL10394905 | 0.72 | POLB (0.63) | — | |
| SCHEMBL1462331 | 0.70 | POLB (0.61) | — | |
| SCHEMBL18226427 | 0.70 | — | — | |
| SCHEMBL2223270 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057048-B | Aminopyrazine/pyridine compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-111057048-A | Aminopyrazine/pyridine compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-20130243741-A1 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2012040105-A2 | RENILLA/GAUSSIA TRANSFECTED CELLS AS A LIGHT SOURCE FOR IN-SITU PHOTODYNAMIC THERAPY OF CANCER | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-03-29 | — | — | WO | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1237880-B1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
| US-6949547-B2 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030216574-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | NUSS JOHN M (US) | 2003-11-20 | — | — | US | disclosed |
| US-6608063-B2 | For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes | CHIRON CORPORATION | 2003-08-19 | — | — | US | disclosed |
| EP-1237880-A2 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001044206-A9 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20010034051-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2001-10-25 | — | — | US | disclosed |
| WO-2001044206-A1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |